<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01251757</url>
  </required_header>
  <id_info>
    <org_study_id>R01HS019341-01</org_study_id>
    <nct_id>NCT01251757</nct_id>
  </id_info>
  <brief_title>Promoting Adherence to Improve Effectiveness of Cardiovascular Disease Therapies</brief_title>
  <acronym>PATIENT</acronym>
  <official_title>Promoting Adherence to Improve Effectiveness of Cardiovascular Disease Therapies (PATIENT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kaiser Permanente</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kaiser Foundation Hospitals, Center for Health Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Agency for Healthcare Research and Quality (AHRQ)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Kaiser Permanente</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this randomized clinical trial is to determine whether two low-intensity,
      technology based interventions, when compared to each other and to usual care, improve
      adherence to selected medications that are used to treat people with cardiovascular disease
      (CVD) and diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The frequent failure of patients to adhere to long-term medication regimens remains the
      single greatest challenge for chronic-disease management. Many studies have linked medication
      non-adherence to treatment failure; unnecessary and dangerous intensification of therapy; and
      excess health care costs, hospitalizations, and deaths. Although some interventions have been
      shown to significantly enhance medication adherence, the strategies used are often complex,
      labor-intensive, and of variable effectiveness. Simple interventions designed to make
      small-but-significant improvements in population-based adherence may thus offer a novel,
      cost-effective, and easily-disseminated alternative to current approaches for enhancing
      adherence. The proposed PATIENT study will use health information technology (automated phone
      calls and access to an electronic medical record) to test two such interventions and compare
      them to each other and to usual care alone.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adherence to Statins</measure>
    <time_frame>12 months post randomization</time_frame>
    <description>We used a modification of the Medication Possession Ratio (MPR) as our primary outcome measure. The MPR is computed as the number of days' supply of medication dispensed during a given time window divided by the time between the first dispensing in the window and the end of the window. Our modified MPR (mMPR) also accounted for medication that was on hand at the start of the window and ignored any days' supply that would extend beyond the end of the window.
We used medication dispensing data from the Kaiser outpatient pharmacies to calculate a modified medication possession ratio (mMPR) for statins among the subset of randomized participants who were using these drugs. Nominally mMPR provides an estimate of the proportion of days during the follow-up period during which the participant was adherent to their prescribed medications.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adherence to Angiotensin-Converting Enzyme Inhibitors (ACEIs) and Angiotensin Receptor Blockers (ARBs)</measure>
    <time_frame>12 months post randomization</time_frame>
    <description>We used medication dispensing data from the Kaiser outpatient pharmacies to calculate a modified medication possession ratio (mMPR) for the subset of randomized participants who were using ACEIs or ARBs. Nominally mMPR provides an estimate of the proportion of days during the follow-up period during which the participant was adherent to their prescribed medications.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage With Good (&gt;80%) Statin Adherence</measure>
    <time_frame>12 months post randomization</time_frame>
    <description>Binary indicator of good statin adherence, defined as an mMPR&gt;0.80. 1=yes, 0=no.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage With Good (&gt;80%) ACEI/ARB Adherence</measure>
    <time_frame>12 months post randomization</time_frame>
    <description>Binary indicator of good ACEI/ARB adherence, defined as an mMPR&gt;0.80. 1=yes, 0=no.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic Blood Pressure (SBP)</measure>
    <time_frame>12-months post randomization</time_frame>
    <description>Mean of last 5 SBP measurements captured in the electronic medical record for the 12 months post randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage With Good (&lt;140/90 mmHg) Blood Pressure Control</measure>
    <time_frame>12 months post randomization</time_frame>
    <description>Using the mean of last 5 available blood pressure measurements post randomization, we defined BP control as a means systolic BP &lt;140 mmHg and a mean diastolic BP &lt; 90 mmHg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post Intervention Low Density Lipoprotein (LDL) Level</measure>
    <time_frame>12 months post randomization</time_frame>
    <description>We used the latest LDL (fasting or nonfasting) available during 12 months post randomization. no missing data were imputed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage With Good (&lt;=100mg/dL) Low Density Lipoprotein (LDL) Control</measure>
    <time_frame>12 months post randomization</time_frame>
    <description>Using the last LDL measurement (fasting or nonfasting) available in the EMR post randomization, we defined good control as an LDL level &lt;= 100 mg/dL.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">21752</enrollment>
  <condition>Diabetes Mellitus</condition>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>Usual Care (UC)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants in this arm received their usual care with no restrictions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Interactive Voice Recognition (IVR)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>automated phone calls</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enhanced IVR (IVR+)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>automated phone calls &amp; Educational mailings and follow-up for nonadherence</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Interactive Voice Recognition (IVR) phone calls</intervention_name>
    <description>The IVR intervention consisted of automated phone calls designed to educate participants about their medications and to assist them in refilling their prescriptions. The calls fell into two basic types: simple refill reminders and &quot;tardy&quot; calls for those who were overdue for a refill. Calls occured monthly and were triggered by dispensing information in the electronic medical record (EMR). Call features included the ability to transfer individuals to Kaiser's automated prescription refill service as well as to care managers. Although the calls were triggered by and focused on use of ACE inhibitors, ARBs and statins, they also included reminders to use aspirin, which is known to also be effective for secondary prevention in this patient population.</description>
    <arm_group_label>Interactive Voice Recognition (IVR)</arm_group_label>
    <arm_group_label>Enhanced IVR (IVR+)</arm_group_label>
    <other_name>automated phone calls</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Educational mailings and follow-up for nonadherence</intervention_name>
    <description>Participants received bimonthly educational materials by mail. In addition, patients received mailed refill reminder letters and their providers were notified electronically if the patients failed to refill in response to the automated calls. The educational mailings included personalized health information such as the participant's cholesterol and blood pressure readings, as well as tools for improving adherence such as frequently asked questions (FAQs) about their medications, a pocket-sized calendar for tracking refills with pertinent phone numbers and web site information and space for them to write their medical record number and prescription numbers.</description>
    <arm_group_label>Enhanced IVR (IVR+)</arm_group_label>
    <other_name>mail follow-up for nonadherence</other_name>
    <other_name>educational mailings</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 40 years or older as of time of randomization.

          -  Flagged in KP's databases as having either diabetes or atherosclerotic cardiovascular
             disease(defined as coronary artery disease, peripheral vascular disease, or a history
             of atherosclerotic stroke) at the time of randomization

          -  At least one dispensing of an ACEI, ARB, or statin from a Kaiser Permanente (KP)
             outpatient pharmacy during the baseline year.

          -  Suboptimal adherence ((MPR&lt;0.9) to either statins or ACEI/ARBs during the baseline
             year

          -  Continuous membership in KP for the 12 months prior to randomization.

          -  Qualified for an intervention call at the time of randomization.

        Exclusion Criteria:

          -  Evidence in the electronic medical record (EMR) of allergy or intolerance to statins
             or ACE inhibitors/ARBs

          -  medical conditions that would contraindicate use of statins or ACEI/ARBs

          -  Absence of either a phone number or mailing address in the EMR

          -  for Kaiser Permanente Hawaii, clinics whose patients tend to fill prescriptions
             primarily at non-KP pharmacies

          -  on Kaiser Permanente's &quot;do not contact&quot; list or in other research studies that could
             add undue burden
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William M Vollmer, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center for Health Research, Kaiser Permanente Northwest</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Health Research, Kaiser Permanente Southeast</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Health Research, Kaiser Permanente Hawaii</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Health Research, Kaiser Permanente Northwest</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Vollmer WM, Owen-Smith AA, Tom JO, Laws R, Ditmer DG, Smith DH, Waterbury AC, Schneider JL, Yonehara CH, Williams A, Vupputuri S, Rand CS. Improving adherence to cardiovascular disease medications with information technology. Am J Manag Care. 2014 Nov;20(11 Spec No. 17):SP502-10.</citation>
    <PMID>25811824</PMID>
  </results_reference>
  <results_reference>
    <citation>Smith DH, O'Keeffe-Rosetti M, Owen-Smith AA, Rand C, Tom J, Vupputuri S, Laws R, Waterbury A, Hankerson-Dyson DD, Yonehara C, Williams A, Schneider J, Dickerson JF, Vollmer WM. Improving Adherence to Cardiovascular Therapies: An Economic Evaluation of a Randomized Pragmatic Trial. Value Health. 2016 Mar-Apr;19(2):176-84. doi: 10.1016/j.jval.2015.11.013. Epub 2016 Feb 12.</citation>
    <PMID>27021751</PMID>
  </results_reference>
  <results_reference>
    <citation>Owen-Smith AA, Smith DH, Rand CS, Tom JO, Laws R, Waterbury A, Williams A, Vollmer WM. Difference in Effectiveness of Medication Adherence Intervention by Health Literacy Level. Perm J. 2016 summer;20(3):38-44. doi: 10.7812/TPP/15-200. Epub 2016 Jun 29.</citation>
    <PMID>27352409</PMID>
  </results_reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2010</study_first_submitted>
  <study_first_submitted_qc>November 30, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2010</study_first_posted>
  <results_first_submitted>July 25, 2016</results_first_submitted>
  <results_first_submitted_qc>December 7, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 1, 2017</results_first_posted>
  <last_update_submitted>February 1, 2017</last_update_submitted>
  <last_update_submitted_qc>February 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>diabetes</keyword>
  <keyword>cardiovascular disease</keyword>
  <keyword>randomized clinical trial</keyword>
  <keyword>medication adherence</keyword>
  <keyword>health information technology</keyword>
  <keyword>adult</keyword>
  <keyword>telephone calls</keyword>
  <keyword>IVR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>At the request of AHRQ we did not create a formal public data release.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Usual Care (UC)</title>
          <description>Participants in this arm had full access to all care they were normally entitled to as part of usual care</description>
        </group>
        <group group_id="P2">
          <title>Interactive Voice Recognition (IVR)</title>
          <description>In addition to their usual care, participants in the Interactive Voice Recognition (IVR) arm received automated phone calls, triggered by dispensing events in the electronic medical record (EMR), to educate patients about their medications and assist them in refilling their prescriptions.
The calls fell into two basic types: simple refill reminders and &quot;tardy&quot; calls for those who were overdue for a refill. Calls occured monthly and were triggered by dispensing information in the EMR. Call features included the ability to transfer individuals to Kaiser's automated prescription refill service as well as to care managers. Although the calls were triggered by and focused on use of ACE inhibitors, ARBs and statins, they also included reminders to use aspirin, which is known to also be effective for secondary prevention in this patient population.</description>
        </group>
        <group group_id="P3">
          <title>Enhanced IVR (IVR+)</title>
          <description>Participants in the IVR+ arm received all components of the IVR intervention and in addition were mailed educational materials bimonthly during the intervention. In addition, both IVR+ participants and their primary care providers received mailed notifications when they did not fill their medications in response to the automated calls.
The educational mailings included personalized health information such as the participant's cholesterol and blood pressure readings, as well as tools for improving adherence such as FAQs about their medications, a pocket-sized calendar for tracking refills with pertinent phone numbers and web site information and space for them to write their medical record number and prescription numbers.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7255">Separate analyses were done for statin users and ACEI/ARB users. This is the combined N.</participants>
                <participants group_id="P2" count="7247">Separate analyses were done for statin users and ACEI/ARB users. This is the combined N.</participants>
                <participants group_id="P3" count="7250">Separate analyses were done for statin users and ACEI/ARB users. This is the combined N.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7255">mean (SD) duration of follow-up was 9.7 (2.3) mos, but we computed an adherence score for everyone.</participants>
                <participants group_id="P2" count="7247">mean (SD) duration of follow-up was 9.6 (2.4) mos, but we computed an adherence score for everyone.</participants>
                <participants group_id="P3" count="7250">mean (SD) duration of follow-up was 9.6 (2.5) mos, but we computed an adherence score for everyone.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized participants</population>
      <group_list>
        <group group_id="B1">
          <title>Usual Care (UC)</title>
          <description>Participants in this arm had full access to all care they were normally entitled to as part of usual care</description>
        </group>
        <group group_id="B2">
          <title>Interactive Voice Recognition (IVR)</title>
          <description>In addition to their usual care, participants in the Interactive Voice Recognition (IVR) arm received automated phone calls, triggered by dispensing events in the electronic medical record (EMR), to educate patients about their medications and assist them in refilling their prescriptions.
The calls fell into two basic types: simple refill reminders and &quot;tardy&quot; calls for those who were overdue for a refill. Calls occured monthly and were triggered by dispensing information in the EMR. Call features included the ability to transfer individuals to Kaiser's automated prescription refill service as well as to care managers. Although the calls were triggered by and focused on use of ACE inhibitors, ARBs and statins, they also included reminders to use aspirin, which is known to also be effective for secondary prevention in this patient population.</description>
        </group>
        <group group_id="B3">
          <title>Enhanced IVR (IVR+)</title>
          <description>Participants in the IVR+ arm received all components of the IVR intervention and in addition were mailed educational materials bimonthly during the intervention. In addition, both IVR+ participants and their primary care providers received mailed notifications when they did not fill their medications in response to the automated calls.
The educational mailings included personalized health information such as the participant's cholesterol and blood pressure readings, as well as tools for improving adherence such as FAQs about their medications, a pocket-sized calendar for tracking refills with pertinent phone numbers and web site information and space for them to write their medical record number and prescription numbers.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7255"/>
            <count group_id="B2" value="7247"/>
            <count group_id="B3" value="7250"/>
            <count group_id="B4" value="21752"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.6" spread="12.2"/>
                    <measurement group_id="B2" value="63.6" spread="12.1"/>
                    <measurement group_id="B3" value="63.5" spread="12.2"/>
                    <measurement group_id="B4" value="63.6" spread="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3432"/>
                    <measurement group_id="B2" value="3370"/>
                    <measurement group_id="B3" value="3415"/>
                    <measurement group_id="B4" value="10217"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3823"/>
                    <measurement group_id="B2" value="3877"/>
                    <measurement group_id="B3" value="3835"/>
                    <measurement group_id="B4" value="11535"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="44"/>
                    <measurement group_id="B4" value="138"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1270"/>
                    <measurement group_id="B2" value="1290"/>
                    <measurement group_id="B3" value="1254"/>
                    <measurement group_id="B4" value="3814"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="798"/>
                    <measurement group_id="B2" value="819"/>
                    <measurement group_id="B3" value="783"/>
                    <measurement group_id="B4" value="2400"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1168"/>
                    <measurement group_id="B2" value="1094"/>
                    <measurement group_id="B3" value="1109"/>
                    <measurement group_id="B4" value="3371"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3403"/>
                    <measurement group_id="B2" value="3399"/>
                    <measurement group_id="B3" value="3408"/>
                    <measurement group_id="B4" value="10210"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="565"/>
                    <measurement group_id="B2" value="602"/>
                    <measurement group_id="B3" value="652"/>
                    <measurement group_id="B4" value="1819"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7255"/>
                    <measurement group_id="B2" value="7247"/>
                    <measurement group_id="B3" value="7250"/>
                    <measurement group_id="B4" value="21752"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ever smokers</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3482"/>
                    <measurement group_id="B2" value="3537"/>
                    <measurement group_id="B3" value="3560"/>
                    <measurement group_id="B4" value="10579"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>no</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3773"/>
                    <measurement group_id="B2" value="3710"/>
                    <measurement group_id="B3" value="3690"/>
                    <measurement group_id="B4" value="11173"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>co-morbid diabetes mellitus</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5666"/>
                    <measurement group_id="B2" value="5703"/>
                    <measurement group_id="B3" value="5626"/>
                    <measurement group_id="B4" value="16995"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>no</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1589"/>
                    <measurement group_id="B2" value="1544"/>
                    <measurement group_id="B3" value="1624"/>
                    <measurement group_id="B4" value="4757"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>co-morbid cardiovascular disease</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2626"/>
                    <measurement group_id="B2" value="2616"/>
                    <measurement group_id="B3" value="2661"/>
                    <measurement group_id="B4" value="7903"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>no</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4629"/>
                    <measurement group_id="B2" value="4631"/>
                    <measurement group_id="B3" value="4589"/>
                    <measurement group_id="B4" value="13849"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>target medication use</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>statin only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2924"/>
                    <measurement group_id="B2" value="2870"/>
                    <measurement group_id="B3" value="2922"/>
                    <measurement group_id="B4" value="8716"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACEI/ARB only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1770"/>
                    <measurement group_id="B2" value="1790"/>
                    <measurement group_id="B3" value="1820"/>
                    <measurement group_id="B4" value="5380"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>statin and ACEI/ARB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2561"/>
                    <measurement group_id="B2" value="2587"/>
                    <measurement group_id="B3" value="2508"/>
                    <measurement group_id="B4" value="7656"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Adherence to Statins</title>
        <description>We used a modification of the Medication Possession Ratio (MPR) as our primary outcome measure. The MPR is computed as the number of days’ supply of medication dispensed during a given time window divided by the time between the first dispensing in the window and the end of the window. Our modified MPR (mMPR) also accounted for medication that was on hand at the start of the window and ignored any days’ supply that would extend beyond the end of the window.
We used medication dispensing data from the Kaiser outpatient pharmacies to calculate a modified medication possession ratio (mMPR) for statins among the subset of randomized participants who were using these drugs. Nominally mMPR provides an estimate of the proportion of days during the follow-up period during which the participant was adherent to their prescribed medications.</description>
        <time_frame>12 months post randomization</time_frame>
        <population>All randomized participants who were taking statins at the time of randomization</population>
        <group_list>
          <group group_id="O1">
            <title>Usual Care (UC)</title>
            <description>statin users in UC arm</description>
          </group>
          <group group_id="O2">
            <title>Interactive Voice Recognition (IVR)</title>
            <description>statin users in IVR arm</description>
          </group>
          <group group_id="O3">
            <title>Enhanced IVR (IVR+)</title>
            <description>statin users in IVR+ arm</description>
          </group>
        </group_list>
        <measure>
          <title>Adherence to Statins</title>
          <description>We used a modification of the Medication Possession Ratio (MPR) as our primary outcome measure. The MPR is computed as the number of days’ supply of medication dispensed during a given time window divided by the time between the first dispensing in the window and the end of the window. Our modified MPR (mMPR) also accounted for medication that was on hand at the start of the window and ignored any days’ supply that would extend beyond the end of the window.
We used medication dispensing data from the Kaiser outpatient pharmacies to calculate a modified medication possession ratio (mMPR) for statins among the subset of randomized participants who were using these drugs. Nominally mMPR provides an estimate of the proportion of days during the follow-up period during which the participant was adherent to their prescribed medications.</description>
          <population>All randomized participants who were taking statins at the time of randomization</population>
          <units>mMPR as a fraction</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5484"/>
                <count group_id="O2" value="5453"/>
                <count group_id="O3" value="5429"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>overall</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5484"/>
                    <count group_id="O2" value="5453"/>
                    <count group_id="O3" value="5429"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.55" spread="0.35"/>
                    <measurement group_id="O2" value="0.57" spread="0.34"/>
                    <measurement group_id="O3" value="0.58" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>baseline adherence &lt;= 0.40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1880"/>
                    <count group_id="O2" value="1827"/>
                    <count group_id="O3" value="1842"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.38" spread="0.37"/>
                    <measurement group_id="O2" value="0.41" spread="0.36"/>
                    <measurement group_id="O3" value="0.41" spread="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>baseline adherence 0.4-0.75</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3165"/>
                    <count group_id="O2" value="3141"/>
                    <count group_id="O3" value="3122"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.61" spread="0.31"/>
                    <measurement group_id="O2" value="0.63" spread="0.31"/>
                    <measurement group_id="O3" value="0.65" spread="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>baseline adherence 0.75-0.90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="439"/>
                    <count group_id="O2" value="485"/>
                    <count group_id="O3" value="465"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.75" spread="0.27"/>
                    <measurement group_id="O2" value="0.77" spread="0.27"/>
                    <measurement group_id="O3" value="0.75" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>We conducted separate primary analyses of each of IVR and IVR+ versus usual care at the .025 level of significance to assure a trial-wide error rate of .05. This analysis summary is for the IVR versus UC comparison only. Also, we only report results here for the full sample, and not also separately for the 3 baseline adherence level groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <method>Regression, Linear</method>
            <method_desc>adjusted for site, gender, age, total number of prescription medications patient is taking, comorbid diabetes/CVD, and baseline statin adherence.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.022</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.011</ci_lower_limit>
            <ci_upper_limit>0.034</ci_upper_limit>
            <estimate_desc>Adjusted difference in adherence for IVR group versus UC group, calculated as IVR - UC.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>We conducted separate primary analyses of each of IVR and IVR+ versus usual care at the .025 level of significance to assure a trial-wide error rate of .05. This analysis summary is for the IVR+ versus UC comparison only. Also, we only report results here for the full sample, and not also separately for the 3 baseline adherence level groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <method>Regression, Linear</method>
            <method_desc>adjusted for site, gender, age, total number of prescription medications participant is taking, comorbid diabetes/CVD, and baseline statin adherence.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.030</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.019</ci_lower_limit>
            <ci_upper_limit>0.042</ci_upper_limit>
            <estimate_desc>Adjusted difference in adherence for IVR+ group versus UC group, calculated as IVR+ - UC.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Adherence to Angiotensin-Converting Enzyme Inhibitors (ACEIs) and Angiotensin Receptor Blockers (ARBs)</title>
        <description>We used medication dispensing data from the Kaiser outpatient pharmacies to calculate a modified medication possession ratio (mMPR) for the subset of randomized participants who were using ACEIs or ARBs. Nominally mMPR provides an estimate of the proportion of days during the follow-up period during which the participant was adherent to their prescribed medications.</description>
        <time_frame>12 months post randomization</time_frame>
        <population>All randomized participants who were taking an ACEI or an ARB at the time of randomization</population>
        <group_list>
          <group group_id="O1">
            <title>Usual Care (UC)</title>
            <description>ACEI/ARB users in UC arm</description>
          </group>
          <group group_id="O2">
            <title>Interactive Voice Recognition (IVR)</title>
            <description>ACEI/ARB users in IVR arm</description>
          </group>
          <group group_id="O3">
            <title>Enhanced IVR (IVR+)</title>
            <description>ACEI/ARB users in IVR+ arm</description>
          </group>
        </group_list>
        <measure>
          <title>Adherence to Angiotensin-Converting Enzyme Inhibitors (ACEIs) and Angiotensin Receptor Blockers (ARBs)</title>
          <description>We used medication dispensing data from the Kaiser outpatient pharmacies to calculate a modified medication possession ratio (mMPR) for the subset of randomized participants who were using ACEIs or ARBs. Nominally mMPR provides an estimate of the proportion of days during the follow-up period during which the participant was adherent to their prescribed medications.</description>
          <population>All randomized participants who were taking an ACEI or an ARB at the time of randomization</population>
          <units>mMPR expressed as a fraction</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4330"/>
                <count group_id="O2" value="4370"/>
                <count group_id="O3" value="4323"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>overall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.57" spread="0.36"/>
                    <measurement group_id="O2" value="0.59" spread="0.35"/>
                    <measurement group_id="O3" value="0.61" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>baseline adherence &lt;=0.50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.45" spread="0.37"/>
                    <measurement group_id="O2" value="0.47" spread="0.37"/>
                    <measurement group_id="O3" value="0.50" spread="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>baseline adherence 0.50-0.75</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.69" spread="0.30"/>
                    <measurement group_id="O2" value="0.70" spread="0.29"/>
                    <measurement group_id="O3" value="0.71" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>baseline adherence 0.75-0.90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.76" spread="0.26"/>
                    <measurement group_id="O2" value="0.76" spread="0.28"/>
                    <measurement group_id="O3" value="0.77" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>We conducted separate primary analyses of each of IVR and IVR+ versus usual care at the .025 level of significance to assure a trial-wide error rate of .05. This analysis summary is for the IVR versus UC comparison only. Also, we only report results here for the full sample, and not also separately for the 3 baseline adherence level groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.022</p_value>
            <method>Regression, Linear</method>
            <method_desc>Adjusted for site, gender, age, total number of prescription medications participant was taking, comorbid diabetes/CVD, baseline ACEI/ARB adherence.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.016</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.002</ci_lower_limit>
            <ci_upper_limit>0.029</ci_upper_limit>
            <estimate_desc>Adjusted difference in adherence for IVR+ group versus UC group, calculated as IVR+ - UC.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>We conducted separate primary analyses of each of IVR and IVR+ versus usual care at the .025 level of significance to assure a trial-wide error rate of .05. This analysis summary is for the IVR+ versus UC comparison only. Also, we only report results here for the full sample, and not also separately for the 3 baseline adherence level groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <method>Regression, Linear</method>
            <method_desc>Adjusted for site, gender, age, total number of prescription medications participant was taking, comorbid diabetes/CVD, baseline ACEI/ARB adherence.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.037</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.023</ci_lower_limit>
            <ci_upper_limit>0.050</ci_upper_limit>
            <estimate_desc>Adjusted difference in adherence for IVR+ group versus UC group, calculated as IVR+ - UC.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage With Good (&gt;80%) Statin Adherence</title>
        <description>Binary indicator of good statin adherence, defined as an mMPR&gt;0.80. 1=yes, 0=no.</description>
        <time_frame>12 months post randomization</time_frame>
        <population>All randomized participants who were taking statins at the time of randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Usual Care (UC)</title>
            <description>statin users in UC arm</description>
          </group>
          <group group_id="O2">
            <title>Interactive Voice Recognition (IVR)</title>
            <description>statin users in IVR arm</description>
          </group>
          <group group_id="O3">
            <title>Enhanced IVR (IVR+)</title>
            <description>statin users in IVR+ arm</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage With Good (&gt;80%) Statin Adherence</title>
          <description>Binary indicator of good statin adherence, defined as an mMPR&gt;0.80. 1=yes, 0=no.</description>
          <population>All randomized participants who were taking statins at the time of randomization.</population>
          <units>percent with good adherence</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5484"/>
                <count group_id="O2" value="5453"/>
                <count group_id="O3" value="5429"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.9"/>
                    <measurement group_id="O2" value="35.9"/>
                    <measurement group_id="O3" value="35.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>baseline adherence &lt;=0.40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.5"/>
                    <measurement group_id="O2" value="22.6"/>
                    <measurement group_id="O3" value="21.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>baseline adherence 0.4-0.75</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.2"/>
                    <measurement group_id="O2" value="39.4"/>
                    <measurement group_id="O3" value="40.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>baseline adherence 0.75-0.90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.1"/>
                    <measurement group_id="O2" value="63.5"/>
                    <measurement group_id="O3" value="62.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>We conducted separate primary analyses of each of IVR and IVR+ versus usual care at the .025 level of significance to assure a trial-wide error rate of .05. This analysis summary is for the IVR versus UC comparison only. Also, we only report results here for the full sample, and not also separately for the 3 baseline adherence level groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <p_value_desc>Adjusted for site, gender, age, total number of prescription medications patient is taking, comorbid diabetes/CVD, and baseline statin adherence.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.05</ci_lower_limit>
            <ci_upper_limit>1.24</ci_upper_limit>
            <estimate_desc>Adjusted odds ratio for good adherence in IVR group versus UC group, calculated as IVR - UC.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>We conducted separate primary analyses of each of IVR and IVR+ versus usual care at the .025 level of significance to assure a trial-wide error rate of .05. This analysis summary is for the IVR+ versus UC comparison only. Also, we only report results here for the full sample, and not also separately for the 3 baseline adherence level groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Adjusted for site, gender, age, total number of prescription medications patient is taking, comorbid diabetes/CVD, and baseline statin adherence.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.06</ci_lower_limit>
            <ci_upper_limit>1.26</ci_upper_limit>
            <estimate_desc>Adjusted odds ratio for good adherence in IVR+ group versus UC group, calculated as IVR+ - UC.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage With Good (&gt;80%) ACEI/ARB Adherence</title>
        <description>Binary indicator of good ACEI/ARB adherence, defined as an mMPR&gt;0.80. 1=yes, 0=no.</description>
        <time_frame>12 months post randomization</time_frame>
        <population>All randomized participants who were taking an ACEI or an ARB at the time of randomization</population>
        <group_list>
          <group group_id="O1">
            <title>Usual Care (UC)</title>
            <description>ACEI/ARB users in UC arm</description>
          </group>
          <group group_id="O2">
            <title>Interactive Voice Recognition (IVR)</title>
            <description>ACEI/ARB users in IVR arm</description>
          </group>
          <group group_id="O3">
            <title>Enhanced IVR (IVR+)</title>
            <description>ACEI/ARB users in IVR+ arm</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage With Good (&gt;80%) ACEI/ARB Adherence</title>
          <description>Binary indicator of good ACEI/ARB adherence, defined as an mMPR&gt;0.80. 1=yes, 0=no.</description>
          <population>All randomized participants who were taking an ACEI or an ARB at the time of randomization</population>
          <units>Percent with good adherence</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4330"/>
                <count group_id="O2" value="4370"/>
                <count group_id="O3" value="4323"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4330"/>
                    <count group_id="O2" value="4370"/>
                    <count group_id="O3" value="4323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.4"/>
                    <measurement group_id="O2" value="40.3"/>
                    <measurement group_id="O3" value="41.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline adherence &lt;=0.50</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2111"/>
                    <count group_id="O2" value="2123"/>
                    <count group_id="O3" value="2155"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.5"/>
                    <measurement group_id="O2" value="27.0"/>
                    <measurement group_id="O3" value="28.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline adherence 0.50-0.75</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1049"/>
                    <count group_id="O2" value="1059"/>
                    <count group_id="O3" value="1058"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.4"/>
                    <measurement group_id="O2" value="51.1"/>
                    <measurement group_id="O3" value="52.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline adherence 0.75-0-.90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="723"/>
                    <count group_id="O2" value="680"/>
                    <count group_id="O3" value="657"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.7"/>
                    <measurement group_id="O2" value="62.0"/>
                    <measurement group_id="O3" value="66.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>We conducted separate primary analyses of each of IVR and IVR+ versus usual care at the .025 level of significance to assure a trial-wide error rate of .05. This analysis summary is for the IVR versus UC comparison only. Also, we only report results here for the full sample, and not also separately for the 3 baseline adherence level groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.014</p_value>
            <p_value_desc>adjusted for site, gender, age, total number of prescription medications participant was taking, comorbid diabetes/CVD, baseline ACEI/ARB adherence</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.02</ci_lower_limit>
            <ci_upper_limit>1.23</ci_upper_limit>
            <estimate_desc>Adjusted odds ratio for good adherence in IVR group versus UC group, calculated as IVR - UC.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>We conducted separate primary analyses of each of IVR and IVR+ versus usual care at the .025 level of significance to assure a trial-wide error rate of .05. This analysis summary is for the IVR+ versus UC comparison only. Also, we only report results here for the full sample, and not also separately for the 3 baseline adherence level groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Adjusted for site, gender, age, total number of prescription medications patient is taking, comorbid diabetes/CVD, and baseline statin adherence.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.10</ci_lower_limit>
            <ci_upper_limit>1.32</ci_upper_limit>
            <estimate_desc>Adjusted odds ratio for good adherence in IVR group versus UC group, calculated as IVR - UC.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systolic Blood Pressure (SBP)</title>
        <description>Mean of last 5 SBP measurements captured in the electronic medical record for the 12 months post randomization.</description>
        <time_frame>12-months post randomization</time_frame>
        <population>The analysis sample was restricted to ACEI/ARB users with at least one post intervention SBP measurement recorded in the EMR. We did not impute any missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Usual Care (UC)</title>
            <description>ACEI/ARB users in UC arm</description>
          </group>
          <group group_id="O2">
            <title>Interactive Voice Recognition (IVR)</title>
            <description>ACEI/ARB users in IVR arm .</description>
          </group>
          <group group_id="O3">
            <title>Enhanced IVR (IVR+)</title>
            <description>ACEI/ARB users in IVR+ arm</description>
          </group>
        </group_list>
        <measure>
          <title>Systolic Blood Pressure (SBP)</title>
          <description>Mean of last 5 SBP measurements captured in the electronic medical record for the 12 months post randomization.</description>
          <population>The analysis sample was restricted to ACEI/ARB users with at least one post intervention SBP measurement recorded in the EMR. We did not impute any missing data.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3980"/>
                <count group_id="O2" value="3980"/>
                <count group_id="O3" value="3971"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3980"/>
                    <count group_id="O2" value="3980"/>
                    <count group_id="O3" value="3971"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="129.2" spread="13.1"/>
                    <measurement group_id="O2" value="128.6" spread="13.2"/>
                    <measurement group_id="O3" value="129.0" spread="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline SBP&lt;=130mmHg</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2111"/>
                    <count group_id="O2" value="2123"/>
                    <count group_id="O3" value="2155"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123.5" spread="10.7"/>
                    <measurement group_id="O2" value="122.8" spread="11.1"/>
                    <measurement group_id="O3" value="123.4" spread="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline SBP 130-140mmHg</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1049"/>
                    <count group_id="O2" value="1059"/>
                    <count group_id="O3" value="1058"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132.8" spread="10.7"/>
                    <measurement group_id="O2" value="132.2" spread="10.1"/>
                    <measurement group_id="O3" value="132.7" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline SBP&gt;140mmHg</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="723"/>
                    <count group_id="O2" value="680"/>
                    <count group_id="O3" value="657"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140.6" spread="13.3"/>
                    <measurement group_id="O2" value="140.4" spread="13.2"/>
                    <measurement group_id="O3" value="140.9" spread="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>We conducted separate primary analyses of each of IVR and IVR+ versus usual care at the .025 level of significance to assure a trial-wide error rate of .05. This analysis summary is for the IVR versus UC comparison only. Also, we only report results here for the full sample, and not also separately for the 3 baseline SBP level groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.041</p_value>
            <p_value_desc>As noted above, the a priori threshold for statistical significance for this test was .025.</p_value_desc>
            <method>Regression, Linear</method>
            <method_desc>Adjusted for site, gender, age, total number of prescription medications patient is taking, comorbid diabetes/CVD, and baseline SBP group.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.0</ci_lower_limit>
            <ci_upper_limit>0.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>We conducted separate primary analyses of each of IVR and IVR+ versus usual care at the .025 level of significance to assure a trial-wide error rate of .05. This analysis summary is for the IVR+ versus UC comparison only. Also, we only report results here for the full sample, and not also separately for the 3 baseline SBP level groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.93</p_value>
            <p_value_desc>As noted above, the a priori threshold for statistical significance for this test was .025.</p_value_desc>
            <method>Regression, Linear</method>
            <method_desc>Adjusted for site, gender, age, total number of prescription medications participant is taking, comorbid diabetes/CVD, and baseline SBP group.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-.5</ci_lower_limit>
            <ci_upper_limit>.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage With Good (&lt;140/90 mmHg) Blood Pressure Control</title>
        <description>Using the mean of last 5 available blood pressure measurements post randomization, we defined BP control as a means systolic BP &lt;140 mmHg and a mean diastolic BP &lt; 90 mmHg.</description>
        <time_frame>12 months post randomization</time_frame>
        <population>All randomized participants who were taking an ACEI or an ARB at the time of randomization and who had at least one post randomization BP recorded in the EMR. Missing data were not imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>Usual Care (UC)</title>
            <description>ACEI/ARB users in UC arm</description>
          </group>
          <group group_id="O2">
            <title>Interactive Voice Recognition (IVR)</title>
            <description>ACEI/ARB users in IVR arm .</description>
          </group>
          <group group_id="O3">
            <title>Enhanced IVR (IVR+)</title>
            <description>ACEI/ARB users in IVR+ arm</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage With Good (&lt;140/90 mmHg) Blood Pressure Control</title>
          <description>Using the mean of last 5 available blood pressure measurements post randomization, we defined BP control as a means systolic BP &lt;140 mmHg and a mean diastolic BP &lt; 90 mmHg.</description>
          <population>All randomized participants who were taking an ACEI or an ARB at the time of randomization and who had at least one post randomization BP recorded in the EMR. Missing data were not imputed.</population>
          <units>percentage of subjects with good control</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3980"/>
                <count group_id="O2" value="3980"/>
                <count group_id="O3" value="3971"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.1"/>
                    <measurement group_id="O2" value="82.1"/>
                    <measurement group_id="O3" value="81.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline SBP&lt;=130 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.7"/>
                    <measurement group_id="O2" value="94.0"/>
                    <measurement group_id="O3" value="92.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline SBP 130-140 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.4"/>
                    <measurement group_id="O2" value="78.4"/>
                    <measurement group_id="O3" value="78.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline SBP&gt;140 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.2"/>
                    <measurement group_id="O2" value="52.4"/>
                    <measurement group_id="O3" value="50.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>We conducted separate primary analyses of each of IVR and IVR+ versus usual care at the .025 level of significance to assure a trial-wide error rate of .05. This analysis summary is for the IVR versus UC comparison only. Also, we only report results here for the full sample, and not also separately for the 3 baseline SBP level groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.404</p_value>
            <p_value_desc>As noted above, the a priori threshold for statistical significance for this test was .025.</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>Adjusted for site, gender, age, total number of prescription medications participant is taking, comorbid diabetes/CVD, and baseline SBP group</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.93</ci_lower_limit>
            <ci_upper_limit>1.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>We conducted separate primary analyses of each of IVR and IVR+ versus usual care at the .025 level of significance to assure a trial-wide error rate of .05. This analysis summary is for the IVR+ versus UC comparison only. Also, we only report results here for the full sample, and not also separately for the 3 baseline SBP level groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.54</p_value>
            <p_value_desc>As noted above, the a priori threshold for statistical significance for this test was .025.</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>Adjusted for site, gender, age, total number of prescription medications participant is taking, comorbid diabetes/CVD, and baseline SBP group</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>.85</ci_lower_limit>
            <ci_upper_limit>1.09</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post Intervention Low Density Lipoprotein (LDL) Level</title>
        <description>We used the latest LDL (fasting or nonfasting) available during 12 months post randomization. no missing data were imputed.</description>
        <time_frame>12 months post randomization</time_frame>
        <population>All randomized participants who were taking statin at the time of randomization and who had at least one post randomization LDL measurement recorded in the EMR. Missing data were not imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>Usual Care (UC)</title>
            <description>statin users in UC arm</description>
          </group>
          <group group_id="O2">
            <title>Interactive Voice Recognition (IVR)</title>
            <description>statin users in IVR arm</description>
          </group>
          <group group_id="O3">
            <title>Enhanced IVR (IVR+)</title>
            <description>statin users in IVR+ arm</description>
          </group>
        </group_list>
        <measure>
          <title>Post Intervention Low Density Lipoprotein (LDL) Level</title>
          <description>We used the latest LDL (fasting or nonfasting) available during 12 months post randomization. no missing data were imputed.</description>
          <population>All randomized participants who were taking statin at the time of randomization and who had at least one post randomization LDL measurement recorded in the EMR. Missing data were not imputed.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4621"/>
                <count group_id="O2" value="4610"/>
                <count group_id="O3" value="4545"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4621"/>
                    <count group_id="O2" value="4610"/>
                    <count group_id="O3" value="4545"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.4" spread="35.3"/>
                    <measurement group_id="O2" value="91.8" spread="34.0"/>
                    <measurement group_id="O3" value="91.3" spread="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline LDL &lt;=80 mg/dL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1815"/>
                    <count group_id="O2" value="1769"/>
                    <count group_id="O3" value="1734"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.5" spread="26.1"/>
                    <measurement group_id="O2" value="75.5" spread="25.7"/>
                    <measurement group_id="O3" value="75.6" spread="26.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline LDL 80-100 mg/dL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1155"/>
                    <count group_id="O2" value="1224"/>
                    <count group_id="O3" value="1193"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.0" spread="27.8"/>
                    <measurement group_id="O2" value="91.5" spread="25.9"/>
                    <measurement group_id="O3" value="90.7" spread="24.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline LDL&gt;100 mg/dL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1352"/>
                    <count group_id="O2" value="1329"/>
                    <count group_id="O3" value="1346"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114.9" spread="37.9"/>
                    <measurement group_id="O2" value="113.0" spread="37.9"/>
                    <measurement group_id="O3" value="111.4" spread="36.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>We conducted separate primary analyses of each of IVR and IVR+ versus usual care at the .025 level of significance to assure a trial-wide error rate of .05. This analysis summary is for the IVR versus UC comparison only. Also, we only report results here for the full sample, and not also separately for the 3 baseline LDL subgroups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.38</p_value>
            <p_value_desc>As noted above, the a priori threshold for statistical significance for this test was .025.</p_value_desc>
            <method>Regression, Linear</method>
            <method_desc>Adjusted for site, gender, age, total number of prescription medications participant is taking, comorbid diabetes/CVD, and baseline LDL group.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.8</ci_lower_limit>
            <ci_upper_limit>0.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>We conducted separate primary analyses of each of IVR and IVR+ versus usual care at the .025 level of significance to assure a trial-wide error rate of .05. This analysis summary is for the IVR+ versus UC comparison only. Also, we only report results here for the full sample, and not also separately for the 3 baseline LDL level subgroups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.019</p_value>
            <p_value_desc>As noted above, the a priori threshold for statistical significance for this test was .025.</p_value_desc>
            <method>Regression, Linear</method>
            <method_desc>adjusted for site, gender, age, total number of prescription medications participant is taking, comorbid diabetes/CVD, and baseline LDL group.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.7</ci_lower_limit>
            <ci_upper_limit>-0.2</ci_upper_limit>
            <estimate_desc>MeanLDL levels were sig lower for IVR+ participants than for UC participants. In subgroup analyses this difference was most pronounced in those individuals with baseline LDL levels above 100 mg/dL (adj diff=-3.6 mg/dL, 95%CI= (-5.9, -1.3), p=.002).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage With Good (&lt;=100mg/dL) Low Density Lipoprotein (LDL) Control</title>
        <description>Using the last LDL measurement (fasting or nonfasting) available in the EMR post randomization, we defined good control as an LDL level &lt;= 100 mg/dL.</description>
        <time_frame>12 months post randomization</time_frame>
        <population>All randomized participants who were taking a statin at the time of randomization and who had at least one post randomization LDL measurement recorded in the EMR. Missing data were not imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>Usual Care (UC)</title>
            <description>statin users in UC arm</description>
          </group>
          <group group_id="O2">
            <title>Interactive Voice Recognition (IVR)</title>
            <description>statin users in IVR arm</description>
          </group>
          <group group_id="O3">
            <title>Enhanced IVR (IVR+)</title>
            <description>statin users in IVR+ arm</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage With Good (&lt;=100mg/dL) Low Density Lipoprotein (LDL) Control</title>
          <description>Using the last LDL measurement (fasting or nonfasting) available in the EMR post randomization, we defined good control as an LDL level &lt;= 100 mg/dL.</description>
          <population>All randomized participants who were taking a statin at the time of randomization and who had at least one post randomization LDL measurement recorded in the EMR. Missing data were not imputed.</population>
          <units>percentage with controlled LDL</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4621"/>
                <count group_id="O2" value="4610"/>
                <count group_id="O3" value="4545"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.1"/>
                    <measurement group_id="O2" value="69.8"/>
                    <measurement group_id="O3" value="70.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline LDL &lt;=80 mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.4"/>
                    <measurement group_id="O2" value="88.0"/>
                    <measurement group_id="O3" value="88.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline LDL 80-100 mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.7"/>
                    <measurement group_id="O2" value="74.0"/>
                    <measurement group_id="O3" value="74.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline LDL &gt; 100 mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.9"/>
                    <measurement group_id="O2" value="43.5"/>
                    <measurement group_id="O3" value="44.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>We conducted separate primary analyses of each of IVR and IVR+ versus usual care at the .025 level of significance to assure a trial-wide error rate of .05. This analysis summary is for the IVR versus UC comparison only. Also, we only report results here for the full sample, and not also separately for the 3 baseline LDL level subgroups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.59</p_value>
            <p_value_desc>As noted above, the a priori threshold for statistical significance for this test was .025.</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>Adjusted for site, gender, age, total number of prescription medications participant is taking, comorbid diabetes/CVD, and baseline LDL group.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.93</ci_lower_limit>
            <ci_upper_limit>1.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>We conducted separate primary analyses of each of IVR and IVR+ versus usual care at the .025 level of significance to assure a trial-wide error rate of .05. This analysis summary is for the IVR+ versus UC comparison only. Also, we only report results here for the full sample, and not also separately for the 3 baseline LDL level subgroups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.058</p_value>
            <p_value_desc>As noted above, the a priori threshold for statistical significance for this test was .025.</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>Adjusted for site, gender, age, total number of prescription medications participant is taking, comorbid diabetes/CVD, and baseline LDL group.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.00</ci_lower_limit>
            <ci_upper_limit>1.22</ci_upper_limit>
            <estimate_desc>Though higher for the IVR+ group, LDL control did not differ significantly between the IVR+ and UC arms. Among those with poor initial control, however, control was sig better for the IVR+ arm (OR = 1.21, 95%CI = (1.04, 1.42), p=.015).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months post randomization</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Usual Care (UC)</title>
          <description>usual medical care</description>
        </group>
        <group group_id="E2">
          <title>Interactive Voice Recognition (IVR)</title>
          <description>usual care plus automated phone calls</description>
        </group>
        <group group_id="E3">
          <title>Enhanced IVR (IVR+)</title>
          <description>usual care plus automated phone calls plus educational mailings and mail follow-up for persistent nonadherence</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="141" subjects_at_risk="7255"/>
                <counts group_id="E2" subjects_affected="146" subjects_at_risk="7247"/>
                <counts group_id="E3" subjects_affected="140" subjects_at_risk="7250"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="7255"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="7247"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="7250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>potential statin related hospitalization</sub_title>
                <description>specifically includes hospitalizations for liver failure or cirrhosis rhabdomyolysis as a primary discharge diagnosis</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3980"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3980"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="3971"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>potential ACEI/ARB related hospitalization</sub_title>
                <description>organ system categorization is incomplete. this includes hospitalization for acute renal failure, angioedema, anaphylactic shock, and anaphylactic hypotension</description>
                <counts group_id="E1" events="24" subjects_affected="24" subjects_at_risk="4330"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="4370"/>
                <counts group_id="E3" events="20" subjects_affected="20" subjects_at_risk="4323"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7247"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7250"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>William M Vollmer, PhD</name_or_title>
      <organization>Kaiser Permanente Center for Health Research</organization>
      <phone>503-335-2400</phone>
      <email>william.vollmer@kpchr.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

